Tyrosine kinase inhibitors for the intervention of major morbid events in myeloproliferative neoplasms：reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.03.005
- VernacularTitle:酪氨酸激酶抑制剂对骨髓增殖性肿瘤主要发病事件的干预：第57届美国血液学会年会报道
- Author:
Guo AI
;
Jianming FENG
;
Wenqian LI
;
Xiuru FAN
;
Shimei LI
;
Xiaorui WANG
;
Qiaolin LI
- Publication Type:Journal Article
- Keywords:
Myeloproliferative neoplasms;
Tyrosine kinase inhibitor;
Intervention;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(3):150-152,156
- CountryChina
- Language:Chinese
-
Abstract:
With the research progress of pathogenesis of JAK gene in myeloproliferative neoplasms (MPN), more tyrosine kinase inhibitors were developed. MPN quantify scoring system is used to determine the efficacy of tyrosine kinase inhibitors for MPN. The choice of tyrosine kinase inhibitors, tyrosine kinase for the relief of MPN symptom burden, etc, become the topics of the 57th American Society of Hematology (ASH) annual meeting.
